Doctor with cancer patient

Context Therapeutics

US: CNTX

Market Cap$28m

Last Close $1.77

Context Therapeutics is a clinical-stage women’s oncology company. Lead candidate ONA-XR is a ‘full’ PR antagonist currently being evaluated in three Phase II clinical trials in hormone-driven breast, endometrial and ovarian cancer. Preliminary data from at least one trial are expected in mid-2022.

More Context Therapeutics content >

Investment summary

Context Therapeutics is a Nasdaq-listed biopharma company developing novel therapeutics focused on women’s oncology indications. Lead programme onapristone extended release (ONA-XR) is a potential first-in-class progesterone receptor (PR) antagonist being evaluated in several mid-stage clinical programmes in advanced HR+/HER2- breast as well as hormone-driven endometrial and ovarian cancer, all areas with significant unmet need and all expected to release preliminary data in 2022. The other asset CLDN6xCD3, is a novel bi-specific monoclonal antibody, acquired in April 2021 and being assessed in endometrial and ovarian cancers. The company held an investor webinar on 13 April to review data from the presentations it made on ONA-XR (as a combination therapy with different therapeutic classes) and CLDN6xCD3 at the American Association for Cancer Research conference.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (fd) (c)
P/E (x)
P/CF (x)
2020A 0.0 (2.6) (3.2) (928.15) N/A N/A
2021A 0.0 (10.5) (10.6) (373.72) N/A N/A
2022E 0.0 (17.1) (16.1) (100.62) N/A N/A
2023E 0.0 (23.0) (22.3) (139.76) N/A N/A
Industry outlook

According to the American Cancer Society, there were an estimated 284,200 breast cancer cases, 66,570 endometrial cancer cases and 21,410 ovarian cancer cases in the US in 2021 (more than 70% of these are hormone-driven). Long-term survival rates remain low in the metastatic setting (c 30% for HR+/HER2- breast cancer) despite recent advances, highlighting the high unmet need in the space.

Last updated on 20/05/2022
Content on Context Therapeutics
Context Therapeutics – R&D webinar highlights pipeline potential
Healthcare | research Update | 22 April 2022
Medicine for woman. Menopause, pms, menstruation or estrogen concept. Female health. Gender symbol made from pink red pills or tablets on wooden table.
Key opinion leader webinar: Context Therapeutics
Healthcare | Edison TV | 22 April 2022
Context Therapeutics – A catalyst-rich year ahead
Healthcare | research Update | 8 April 2022
Medicine for woman. Menopause, pms, menstruation or estrogen concept. Female health. Gender symbol made from pink red pills or tablets on wooden table.
View more
Register to receive research on Context Therapeutics as it is published
Share price graph
Balance sheet
Forecast net cash (US$m) 36.5
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 4.7 (7.8) N/A
Relative* 19.7 2.8 N/A
52-week high/low US$7.5/US$1.3
*% relative to local index
Key management
Martin Lehr CEO
Jennifer Minai-Azary CFO